Since retinal neovascularization is the hallmark of proliferative diabetic retinopathy in humans, we used this retinopathy of prematurity model, in addition to a STZ-induced diabetic retinopathy model, to fully evaluate the effects of DPP4-inhibitor on diabetic retinopathy. The gene discussed is DPP4; the disease is proliferative diabetic retinopathy.